Seeking Alpha

Shares of Amarin (AMRN -3.5%) give back much of yesterday's pop on news that Teva Pharmaceutical...

Shares of Amarin (AMRN -3.5%) give back much of yesterday's pop on news that Teva Pharmaceutical (TEVA) and Par Pharmaceutical (PRX) lost their bid to sell the generic form of Lovaza. The stock had rocketed higher on perceptions that the court ruling would clear the way for Amarin's AMR101 to launch and price without competition from generic Lovaza products.
Comments (2)
  • The pop was legit, and AMRN is a powder keg about to blow. It has everything going for it.
    30 May 2012, 02:25 PM Reply Like
  • Interesting all the hype with Amarin considering they do not any sales of product yet, just a lot of speculation. I am watching the new kid on the block, Pivotal Therapeutics, PVTTF:US who already have their Omega3 product being prescribed by doctors and are showing sales NOW! Very cheap stock since it is a new upstart, but do check out their management team & board, very impressive....could be a real sleeping giant.
    4 Jun 2012, 04:05 PM Reply Like
DJIA (DIA) S&P 500 (SPY)